Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Friday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of BTX stock opened at $0.52 on Friday. The company has a 50-day moving average of $1.03 and a two-hundred day moving average of $1.57. The firm has a market cap of $30.59 million, a PE ratio of -0.23 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.